Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A receptor alpha 6 subunit (GABRA6) is a critical component of pentameric ligand-gated chloride channels that mediate fast inhibitory neurotransmission in the central nervous system. Unlike other alpha subunits, the alpha 6 isoform is highly localized, primarily expressed in the cerebellar granule cells and the cochlear nucleus, where it contributes significantly to tonic inhibition rather than just phasic synaptic transmission. This unique distribution makes it an attractive target for treating specific neurological conditions like tinnitus and essential tremor without the widespread sedative or amnestic side effects associated with non-selective GABAergic drugs. Research indicates that alpha 6-containing receptors are insensitive to classical benzodiazepines but can be modulated by specific compounds like DK-I-56-1, offering a pathway for precision pharmacology in sensory and motor disorders.
Positive allosteric modulation, Negative allosteric modulation, Antagonism
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha 6 subunit (GABRA6) (GABRA6).